

Malignant Melanoma Treatment Market -Opportunities, Share, Growth and Competitive Analysis and Forecast 2029


The Business


Research Company

The Business Research Company

The Business Research Company's Malignant Melanoma Treatment Global Market Report 2025 – Market Size, Trends. And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, October 15, 2025 /EINPresswire.com/ -- What Is The Projected Market Size & Growth Rate








Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

The Business Research
Company



research initiatives, and regulatory greenlights.

The market for treating malignant melanoma is predicted to experience significant expansion in the upcoming years. A compound annual growth rate (CAGR) of 10.6% is projected to drive the market size to ""\$11.93 billion by 2029. This market surge in the prediction horizon can be credited to the advent of personalized medical therapies, worldwide health strategies, comprehensive genomic profiling, value-oriented health care frameworks, and

patient-centered approaches. The market trends over the anticipated period include the incorporation of artificial intelligence (AI), technologies for early detection, utilization of real-world evidence and data analysis, the introduction of precision medicine, as well as combined therapies.

Download a free sample of the malignant melanoma treatment market report: https://www.thebusinessresearchcompany.com/sample.aspx?id=13252&type=smp

What Are The Core Growth Drivers Shaping The Future Of The Malignant Melanoma Treatment Market?

The rising exposure to ultraviolet (UV) radiation is anticipated to drive the growth of the malignant melanoma treatment market in the coming years. UV radiation, a form of electromagnetic radiation, has a wavelength shorter than visible light but longer than X-rays. Among the types, UVA (315–400 nm) and UVB (280–315 nm) are particularly linked to the development of malignant melanoma. This is because UV radiation can damage the DNA in skin cells, causing mutations that lead to uncontrolled cell growth and tumor formation. For example, in February 2023, the Melanoma Research Foundation, a U.S.-based organization, reported 1,87,000 melanoma cases in the United States. This number increased by 7.3%, reaching 2,00,651 in 2024. Furthermore, in February 2024, the United States Environmental Protection Agency stated that skin cancer is the most prevalent cancer in the U.S., with unprotected UV exposure being the main preventable cause, impacting one in five Americans during their lifetime. As a result, the growing exposure to UV radiation is fueling the expansion of the malignant melanoma treatment market.

Which Companies Are Currently Leading In The Malignant Melanoma Treatment Market? Major players in the Malignant Melanoma Treatment Global Market Report 2025 include:

- Johnson & Johnson Private Limited
- Pfizer Inc.
- Hoffmann-La Roche AG
- Bayer AG
- Novartis AG
- Merck & Co. Inc.
- GlaxoSmithKline PLC
- Bristol-Myers Squibb Company
- · Sanofi S.A.
- AstraZeneca PLC.

What Are The Top Trends In The Malignant Melanoma Treatment Industry? In the malignant melanoma treatment market, leading businesses are concentrating on formulating innovative drugs and obtaining their certifications to maintain their market presence. Approvals for drugs related to malignant melanoma are on the rise, due to the increased demand for safer and more effective treatments such as Opdualag, which offers a novel therapeutic strategy. Opdualag, a combined fixed-dose of two immunotherapy drugs, nivolumab and relatlimab-rmbw, is utilized for the treatment of unresectable or metastatic melanoma. As a case in point, the US pharmaceutical company Bristol Myers Squibb attained approval for Opdualag from the Food and Drug Administration in March 2022, which is given as a solo intravenous infusion for specific forms of melanoma. This pioneering fixed-dose blend of nivolumab and relatlimab is meant to treat patients aged 12 and over who are affected by metastatic or unresectable melanoma. Relatlimab-rmbw, a human IgG4 monoclonal antibody, is designed to latch onto the LAG-3 receptor. Opdualag serves as a crucial aspect of BMS's cancer

treatment offerings, and its introduction has been well-received, fuelling the company's expansion.

Comparative Analysis Of Leading Malignant Melanoma Treatment Market Segments The malignant melanoma treatmentmarket covered in this report is segmented –

- 1) By Treatment: Immunotherapy; Radiation Therapy; Chemotherapy; Other Treatments
- 2) By Disease Type: Lentigo Maligna Melanoma; Acral Lentiginous Melanoma; Nodular Melanoma; Superficial Spreading Melanoma
- 3) By End-User: Hospitals; Specialty clinics; Other End Users

Subsegments:

- 1) By Immunotherapy: Checkpoint Inhibitors; Cytokine Therapy; Oncolytic Virus Therapy
- 2) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Radiation Therapy
- 3) By Chemotherapy: Traditional Chemotherapy Agents; Combination Chemotherapy Regimens
- 4) By Other Treatments: Targeted Therapy; Surgical Interventions; Clinical Trials For Novel Therapies

View the full malignant melanoma treatment market report:

https://www.thebusinessresearchcompany.com/report/malignant-melanoma-treatment-global-market-report

Which Regions Are Dominating The Malignant Melanoma Treatment Market Landscape? In 2024, North America led the <u>global malignant melanoma treatment market</u>, with Asia-Pacific anticipated to experience the quickest growth in the future. The report on this global market covers regions such as North America, Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa.

Browse Through More Reports Similar to the <u>Global Malignant Melanoma Treatment Market</u> 2025, <u>By The Business Research Company</u>

Malignant Mesothelioma Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/malignant-mesothelioma-global-market-

report

Malignant Pleural Effusion Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/malignant-pleu

https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report

Malt Diastase Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/malt-diastase-global-market-report

Speak With Our Expert:

Saumya Sahay Americas +1 310-496-7795 Asia +44 7882 955267 & +91 8897263534 Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

Χ

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook

This press release can be viewed online at: https://www.einpresswire.com/article/858112539

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.